 | | Vol. 4.33 – 4 September, 2020 |
| |
|
|
| Scientists demonstrated that Kupffer cells (KCs) were reduced in metabolic-associated fatty liver disease, being replaced by macrophages originating from the bone marrow. Recruited macrophages existed in two subsets with distinct activation states, either closely resembling homeostatic KCs or lipid-associated macrophages from obese adipose tissue.
[Immunity] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors showed that fluoxazolevir inhibited fusion of hepatitis C virus (HCV) with hepatic cells by binding HCV envelope protein 1 to prevent fusion.
[Nature Microbiology] |
|
|
|
| Investigators demonstrated that breast cancer-derived extracellular vesicles activated liver sinusoidal endothelial cells in the liver-chip, inducing endothelial to mesenchymal transition and destruction of vessel barriers.
[ACS Nano] |
|
|
|
| Scientists showed that aberrantly activated hepatocyte-intrinsic cell cycle-related kinase signaling in chronic liver diseases was critical for cancer metastasis by reprogramming an immunosuppressive microenvironment.
[Cellular & Molecular Immunology] |
|
|
|
| Researchers investigated the effect of human fetal skin-derived stem cell (hFSSC) secretome in the treatment of liver fibrosis. They investigated the anti-fibrotic mechanism of hFSSC secretome in hepatic stellate cells.
[Stem Cell Research & Therapy] |
|
|
|
| Investigators used state-of-the-art in vitro and in vivo hepatitis B virus (HBV) infection models to evaluate a role for HBV infection and the viral regulatory protein HBx to drive HIF-signaling.
[Scientific Reports] |
|
|
|
| Researchers developed an in vitro system of hepatitis B virus (HBV) infection using iPSC-derived liver cells, and showed that epidermal growth factor secreted from liver sinusoidal endothelial cells modulated HBV infection in a dose-dependent manner.
[Scientific Reports] |
|
|
|
| The authors explored the molecular mechanisms and biological significance of regulatory factor X-5 (RFX5). Firstly, by analyzing ENCODE chromatin immunoprecipitation-seq in HepG2 and TCGA RNA-seq data, they discovered lysine-specific demethylase 4A to be a major downstream target gene of RFX5.
[Scientific Reports] |
|
|
|
| While deltamethrin was rapidly metabolised in vitro, the hepatocyte membrane did not appear to represent a barrier to the absorption and hence subsequent hepatic metabolism of this pyrethroid.
[Xenobiotica] |
|
|
|
|
| Scientists summarize recent developments in the liquid biopsy oncological space and, in more detail, the potential implications in the clinical management of hepatocellular carcinoma. They further outline technical peculiarities across liquid biopsy technologies, which might be helpful for interpretation by non-experts.
[Gut] |
|
|
|
| The authors summarize the state-of-the-art and upcoming technologies of regenerative hepatology that are emerging as promising alternatives to the current standard-of care in liver disease.
[Digestive and Liver Disease] |
|
|
|
|
| Madrigal Pharmaceuticals, Inc. announced that it has already exceeded the originally targeted enrollment of 700 patients in its MAESTRO NAFLD-1 clinical trial of resmetirom in patients with NASH and fibrosis that is diagnosed using non-invasive assessments.
[Madrigal Pharmaceuticals, Inc. (GlobeNewswire, Inc.)] |
|
|
|
| Two years after nabbing three novel anti-infective drug candidates from Swiss pharma giant Novartis for the treatment of antibiotic-resistant infections, Boston Pharma has struck another deal, this time for a potential treatment for non-alcoholic steatohepatitis (NASH).
[Boston Pharmaceuticals (BioSpace)] |
|
|
|
| Engitix Ltd. is developing a portfolio of programmes in fibrosis and solid tumours using its proprietary human extracellular matrix platform. They have entered into a licensing and collaboration agreement with Takeda Pharmaceutical Company Ltd. to discover and develop novel therapeutics for advanced fibrotic liver diseases, including non-alcoholic steatohepatitis.
[Engitix Ltd. ] |
|
|
|
|
|
|
|
| | Institute for Virology, University Hospital Cologne – Cologne, Germany |
|
|
|
| | Texas Biomedical Research Institute – San Antonio, Texas, United States |
|
|
|
| | Foundation for Liver Research – London, England, United Kingdom |
|
|
|
| | Johns Hopkins University School of Medicine – Baltimore, Maryland, United States |
|
|
|
| | Research Institute at Nationwide Children’s Hospital – Columbus, Ohio, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
